# الآيسة

(رَبِّ أَوْزِعْنِي أَنْ أَشْكُرَ نِعْمَتَكَ الَّتِي أَنْعَمْتَ عَلَيَّ وَكُنْ أَشْكُر نِعْمَتَكَ الَّتِي أَنْعَمْتَ عَلَيَّ وَعَلَى وَالِدَيُّ وَأَنْ أَعْمَلَ صَالِحاً تَرْضَاهُ وَأَدْخِلْنِي وَعَلَى وَالِدَيُّ وَأَنْ أَعْمَلَ صَالِحاً تَرْضَاهُ وَأَدْخِلْنِي بِرَحْمَتِكَ فِي عِبَادِكَ الصَّالِحِينَ } برحْمَتِكَ فِي عِبَادِكَ الصَّالِحِينَ }

صدق الله العظيم

سورةالنمل،الآية (19)



I would like to dedicate this research to all those who always have been there for me.

To to the souls of my Father and mother

To my wife and son..

With much love ....

Isam

# Acknowleagments

My greatest depth of gratitude must go to the Staff College of Graduates Studies, of them I would like to thank my supervisor, Dr. Mogahid Mohamed El Hassan who saved me from insensitivities and obscurities of research by his firm guidance and superior standing and knowledge.

My thanks are extended to my colleagues for their kind support and their beautiful friendship.

I would also like to thank my old and little family for their patience and support.

#### **Abstract**

The spread of multidrug-resistant (MDR) strains of *Mycobacterium tuberculosis* has become a major public health concern since these bacteria often cause incurable disease, even when expensive second- and third-line drugs are available.

This study aimed to identify *M. tuberculosis* among suspected tuberculous patients in Khartoum and Gazeera States by using conventional methods also to identify rifampicin resistance *M. tuberculosis* by amplifying rpoB gene, using polymerase chain reaction (PCR). Moreover, it aimed to detect *M. tuberculosis* from direct sputum by PCR.

Out of 228 of sputum samples, 128 and 100 were collected from suspected tuberculosis patients in Khartoum and Gezeera states respectively. Smears were made stained directly using Ziehl-Neelsen (ZN) stain. The results showed that, among Khartuom state suspected patients, 36 (21.7%) were positive for acid fast bacilli (AFB) while 92 (78.3) were negative, and among Gazeera state suspected patients 23(23%) were positive while 77 (77%) were negative. All sputum samples from Khartuom were inoculated on Lowenstein Jensen (LJ) medium and incubated aerobically at 37°C, the isolates showed obvious growth in 46 (36%) whereas 82 (64%) showed no growth, while samples from Gazeera were suspected to direct to PCR.

Selected biochemical tests were performed to all *Mycobacterium tuberculosis* complex (MTC) isolates of Khartuom state, the results revealed that all isolates were sensitive to Para-nitro benzoic acid (growth was inhibited by PNB), resistant to thiophene - 2 - carboxylic acid

hydrazide (TCH), positive for nitrate reduction and were catalase negative at 68°C.

All the forty six isolates that showed typical growth of MTC on LJ medium were subjected to PCR to amplify IS 6110 gene. The results indicate clearly that all isolates showed 123bp bands for IS6110 gene, Drug sensitivity tests were performed to all isolates, the results showed that 26(20.3%) as MDR-TB, 16 (34.8%) as sensitive to rifampicin, Isoniazid, Ethambutol and streptomycin, 2 (4.4%) as resistance to streptomycin, and 2(4.4%) as triple resistance to Isoniazid, Ethambutol and streptomycin.

The twenty six resistant isolates were subjected to PCR searching for rifampicin resistance gene (rpoB) with band equal to 193bp in size, the results showed existence of this band in 20.3% of the mycobacterium tuberculosis isolates, of them 86.7% had resistance to rpoB gene.

Regarding Gazeera state, out of 74 isolates the resistant strains were 25 (33%) only 19 (19%) gave band typical in size to the target gene rpoB (193bp) as indicated by standard DNA ladder for the present of rifampicin resistant gene, of them 76% had resistance to rpoB gene.

Due to the low sensitivity of ZN technique and the long time required to conduct drug susceptibility test (DST) through conventional method, the results concluded the PCR is a valuable, rapid and sensitive technique which can replace conventional method, and PCR is also useful when taken directly from sputum.

The study recommended that, PCR assay could be introduced as a diagnostic tool for tuberculosis, and recommended to support the development of new tools and enable their timely and effective use.

#### مستخلص الرسالة

بات انتشار المنفطرة السلية متعددة المقاومة للادوية من الشواغل الرئيسية للصحة العامة حيث ان هده البكتريا غالبا ما تسبب مرض عضال, بتوفر الادوي البديلة باهظة التمن.

هدفت هذه الدراسة للتعرف على المنفطرة السليب بين المرضى المشتبه إصابتهم

كل من ولاية الخرطوم و ولاية الجزيرة ، باستخدام الطرق التقليدية، والتعرف علي الجين (rpoB) المفاوم للمضاد ريفامبيسينبين السل متعدد المفاومة للادوية باستخدام تفاعل الجين البلمرة التسلسلي والدي المنافعة العزل المنفطرة السلية مباشرة من كهدف اخر.

من بين 228 من المرضى المشتبه إصابتهم بمرض السل تم جمع عدد منه وتمان وعشرون عينة من الخرطوم ومائة من الجزيرة.

ZN. أظهرت النتائج أنه من بين عينات ولاية الخرطوم36 (21%) كانت موجبه للعصيات المقاومة للاحماض، بينما 92 (78.3%) كانت سالبة. ولدى ولاية الجزيرة (23%) كانت موجبه للعصيات المقاومه للاحماض بينما 77 (77%) كانت سالبه.

فيما يخص المجموعة و لاية الخرطوم 46 (36) كانت نتائج موجبة لتزريع المنفطرة السلبب في وسط ليونيستين جنسن عند درجة حرارة 30° و 82 (64) اظهرت . وقد خضعت العينات من و لاية الجزيرة مباشرة لتفاعل البلمرة التسلسلي.

العينات الموجبة للتزريع خضعت للاختبارات البيوكميائية و اظهرت (100) لحامض البرانايتروبنزويك) مقاومة لحامض البرانايتروبنزويك) مقاومة للتيوفين 2- حمض كاربوكسيليك اسيد هيدرازيد ، موجبة لاختبار اختزال النترات وكانت سلبية لاختبار الكتاليزفي درجة حرارة 68 °م.

اظهرت اختبارات الحساسية للادوية ان 26 (20.3) منفطرة , متعددة المقاومة للادوية (34.8) فلنوع الاول من لادوية, سلالتين (4.4) مقاومة للادوية (34.8) فقط للستربتوميسين و الإيتامبوتول. فقط للستربتومايسين ، وسلالتين تلاتية المقاومة للايزونيزايد, الستربتوميسين و الإيتامبوتول. ستة واربعون (36) من عزل المنفطرة السلي اختبرت بواسطة تفاعل البلمرة التسلسلي. (100) من العزلات اظهرت حزمة مطابقة في القياس (123 bp) للجين المستهدف (156 من عزلات المنقطرة السلي المقاومة للادوية اختبرت بواسطة تفاعل البلمرة التسلسلي للجين المقاوم للرفامبسين اظهرت حزمة مطابقة في القياس (193bp). و20.3)

اما فيما يخص المجموعة ولاية الجزيرة خمسة وعشرون (25%) من عزلات المنفطرة السلي المقاومة للادوية اختبرت بواسطة تفاعل البلمرة التسلسلي للجين المقاوم للرفامبسين وكانت موجبة، بينما تسعة عشر (19%) اظهرت حزمة مطابقة في القياس (193bp) وكانت من بينهم (76%) مقاومة للجين (rpoB).

نتيجة لانخفاض حساسية الصبغه المفاومة للاحماض الفترة الطويلة المستغرفة لاداء التزريع واختبار الحساسية للادوية اظهرت النتائج بوضوح اهمية وحساسية وجدوى تفاعل البلمرة التسلسلي كاداة سريعة للتشخيص والكشف عن المتفطرة السلبية وللجين المقاوم للرفامبسين. كما انه يمكن استخدام تفاعل البلمرة التسلسلي مباشرة من الحشعة المريض.

اوصت الدر اسشة بضرورة اعتبار تفاعل البلمرة التسلسلي كاداة تسخيصية لمرض السل، كما اوصت بدعم وتطوير وسائل التشخيص الحديثة وتقييم نتائجها السريعة والدقيقة.

### LIST OF CONTENTS

| Topic   | Page |  |
|---|------|--|
| آية من القرآن الكريم  | I    |  |
| Dedication  | II   |  |
| Acknowledgment  | III  |  |
| Abstract (English)  | IV   |  |
| Abstract (Arabic)   | V    |  |
| List of content   | VI   |  |
| CHAPTER ONE INTRODUCTION AND OBJECTIVES                     |      |  |
| 1.1 Introduction  | 1    |  |
| 1.2 Rationale   | 3    |  |
| 1.3 Objectives  | 3    |  |
| 1.3.1 General objective                                     | 3    |  |
| 1.3.2 Specific Objectives                                   | 3    |  |
| CHAPTER TWO   |      |  |
| LITERATURE REVIEW   |      |  |
| 2.1 Genus Mycobacterium                                     | 4    |  |
| 2.1.1 Definition and Taxonomy                               | 4    |  |
| 2.1.2 Mycobacterial Taxonomy                                | 5    |  |
| 2.1.3 Classification  | 6    |  |
| 2.1.4 Morphology and Structure Characteristics              | 7    |  |
| 2.1.5 Microbiologic Characteristics of the Genus            | 8    |  |
| 2.1.6 Mycobacterium tuberculosis Complex                    | 8    |  |
| 2.3 2.1.7 The Cell Wall                                     | 9    |  |
| 2.1.8 Nutritional and Environmental Requirements for Growth | 10   |  |
| 2.1.9 Metabolic and Biochemical Markers                     | 11   |  |
| 2.1.10 Resistance to Physical and Chemical Challenges       | 13   |  |
| 2.2 Pathogenesis  | 13   |  |
| 2.2.1 Virulence Mechanisms                                  | 13   |  |
| 2.2.2 Tuberculosis  | 14   |  |
| 2.2.3 Primary Tuberculosis                                  | 14   |  |
| 2.2.4 Secondary or Reactivated Tuberculosis                 | 15   |  |
| 2.2.5 Mode of Transmissions                                 | 15   |  |
| 2.2.6 Prognosis   | 15   |  |
| 2.2.7 Clinical Feature                                      | 16   |  |
| 2.2.7.1 Pulmonary Disease                                   | 16   |  |
| 2.2.7.2 Tuberculosis Meningitis                             | 16   |  |
| 2.2.7.3 Lymph Node Tuberculosis                             | 17   |  |
| 2.2.7.4 Bone and Joint Tuberculosis                         | 17   |  |
| 2.2.7.5 Gastrointestinal Disease                            | 18   |  |
| 2.2.7.6 Cutaneous Tuberculosis                              | 18   |  |
| 2.2.7.7 Genitourinary Tuberculosis                          | 18   |  |
| 2.3 Epidemiology  | 19   |  |
| 2.4 Laboratory Diagnosis                                    | 21   |  |
| 2.4.1 Conventional Methods for Identifying MTB              | 22   |  |
| 2.4.1.1 Microscopic   | 22   |  |

| 2.4.1.2 Traditional Culture Techniques                              | 22 |
|---|----|
| 2.4.1.3 Biochemical Tests for Identification of MTB                 | 23 |
| 2.4.1.4 Immunological Diagnosis                                     | 24 |
| 2.4.1.5 Molecular Diagnosis   | 24 |
| 2.4.1.5.1 Classical Polymerase Chain Reaction Method                | 24 |
| 2.5 Susceptibility Tests for MTB                                    | 25 |
| 2.6 Treatment   | 26 |
| 2.7 Multidrug Resistance Tuberculosis (MDR)                         | 27 |
| 2.7.1 Epidemiology of Multidrug-Resistant TB                        | 28 |
| 2.8 Molecular Basis of Drug Resistance                              | 30 |
| 2.9 Rifampicin  | 30 |
| 2.10 Management of Drug-Resistant Tuberculosis                      | 31 |
| CHAPTER THREE   |    |
| MATERIAL AND METHODS  |    |
| 3.1 Study Design  | 33 |
| 3.1.1. Type of The Study  | 33 |
| 3.1.2. Study Area   | 33 |
| 3.1.3. Study Population   | 33 |
| 3.1.4 Sample Size   | 33 |
| 3.2 Collection of Specimens   | 33 |
| 3.3 Conventional Identification of Mycobacterium species            | 33 |
| 3.3.1 Direct Ziehl-Neelsen Stain                                    | 34 |
| 3.3.2 Culture of Mycobacteria                                       | 34 |
| 3.3.2.1 Culture Media   | 34 |
| 3.3.2.2 Decontamination of Specimens                                | 34 |
| 3.3.3 Isolation and Preservation Techniques                         | 34 |
| 3.3.3.1 Isolation   | 34 |
| 3.3.3.2 Preservation  | 35 |
| 3.3.4 Identification  | 35 |
| 3.3.4.1 Primary Identification                                      | 35 |
| 3.3.4.1.1 Growth Rate   | 35 |
| 3.3.4.1.2 Pigment Production  | 35 |
| 3.3.4.2 Biochemical Test  | 36 |
| 3.3.4.2.1 Catalase Test   | 36 |
| 3.3.4.2.1.1 Heat Stable Catalase Test at (pH7/68 <sup>0</sup> C)    | 36 |
| 3.3.4.2.1.2 Semi-quantitative Catalase Test                         | 36 |
| 3.3.4.2.2 Nitrate Reduction Test                                    | 36 |
| 3.3.4.2.3 Para Nitro-benzoic Acid (PNB) 500mg/l Susceptibility Test | 37 |
| 3.3.4.2.4 Thiophen-2-carboxylic Acid Hydrazide (TCH) 5ug/ml         | 37 |
| Susceptibility Test   | 37 |
| 3.3.5 Drug Susceptibility Test (DST) (Proportion Method)            | 37 |
| 3.3.5.1 Preparation of Stock Solution for Drugs                     | 38 |
| 3.3.5.1.1 Isoniazid   | 38 |
| 3.3.5.1.2 Rifampicin  | 38 |
| 3.3.5.1.3 Dihydro-Streptomycin Sulfate                              | 38 |
| 3.3.5.1.4 Ethambutol  | 38 |
| 3.3.6 Preparation of Drug Containing Media                          | 38 |
| 3.3.6.1 Para Nitro-benzoic Acid                                     | 39 |

| 3.3.6.2 Thiophen-2-carboxylic Acid Hydrazide       | 39 |  |
|--|----|--|
| 3.3.7 Quality Control of Prepared Media            | 39 |  |
| 3.3.8 Preparation of Bacillary Suspension          | 39 |  |
| 3.3.9 Preparation of McFarland Solution I          | 40 |  |
| 3.3.2 Polymerase Chain Reaction Method             | 40 |  |
| 3.3.2.1 DNA Extraction by Phenol-Chloroform        | 40 |  |
| 3.3.2.2 Primers of Insertion Sequence IS6110       | 40 |  |
| 3.3.2.3 Primers for rpoB 273 and rpo B105          | 40 |  |
| 3.3.2.4 Preparation of PCR Mixture                 | 41 |  |
| 3.3.2.5 Polymerase Chain Reaction (PCR)            | 41 |  |
| 3.3.2.6 Preparation of Agarose gel                 | 41 |  |
| 3.3.2.7 Visualization of PCR Product               | 41 |  |
| CHAPTER FOUR                                       |    |  |
| RESULT   |    |  |
| 4.1 Epidemiological Findings                       | 43 |  |
| 4.1.1 Gender                                       | 43 |  |
| 4.1.2 Age Group                                    | 44 |  |
| 4.2 Bacteriological Findings                       | 45 |  |
| 4.2.1 Direct Ziel-Neelsen Staining                 | 45 |  |
|  |    |  |
| 4.2.2 Sensitivity of Smears vs. Culture            | 46 |  |
| 4.2.3 Drug Susceptibility Test                     | 47 |  |
| 4.2.4 Isolates of MTB                              | 48 |  |
| 4.2.5 Growth Rate                                  | 48 |  |
| 4.2.6 Indirect Ziehl-Neelsen Staining              | 48 |  |
| 4.2.7 Cultural Characteristics                     | 49 |  |
| 4.2.8 Biochemical Tests                            | 50 |  |
| 4.1.9 Treatment status                             | 50 |  |
| 4.2.10 Drugs susceptibility Test                   | 52 |  |
| 4.3 Polymerase chain Reaction from culture         | 53 |  |
| 4.3.1 Amplification of the IS6110 Target Sequences | 53 |  |
| 4.3.2 Detection of rpoB Gene                       | 54 |  |
| 4.4 Polymerase chain Reaction from direct sputum   | 55 |  |
| 4.3.1 Amplification of the IS6110 Target Sequences | 55 |  |
| 4.4.2 Detection of rpoB Gene                       | 56 |  |
| CHAPTER FIVE                                       |    |  |
| DISCUSSION   |    |  |
| Discussion   | 57 |  |
| CHAPTER SIX  | -  |  |
| CONCLUSION AND RECOMMENDATIONS                     |    |  |
| 6.1 Conclusion                                     | 61 |  |
| 6.2 Recommendations                                | 62 |  |
| References   | 63 |  |
| APPENDICES   |    |  |
| Appendix-I   | 74 |  |
| Appendix-II  | 75 |  |
| Appendix-III                                       | 76 |  |
| Questionnaire                                      | 77 |  |

## **List of Figures**

| Figure   | Page |
|--|------|
| <b>Figure 1:</b> Distribution of patients with pulmonary infection according to gender in Khartoum and Gazeera.    | 43   |
| <b>Figure2:</b> Correlation between age and Tuberculosis infection among target population in Khartoum and Gazeera | 44   |
| <b>Figure 3:</b> The results of direct smears using ZN technique among enrolled patients in Khartoum and Gazeera   | 45   |
| <b>Figure 4.</b> The results of culture technique among an enrolled patients in Khartoum state.                    | 47   |
| <b>Figure 5.</b> The results of drug susceptibility test among target patients in Khartoum State                   | 48   |
| <b>Figure 6.</b> Result of indirect ZN stains showing acid fast bacilli  | 49   |
| <b>Figure 7</b> . Characteristic growth of a 3 weeks old culture of <i>M. tuberculosis</i> on LJ medium            | 50   |
| <b>Figure 8</b> . Results of catalase test; positive to the left side and negative on right side                   | 52   |
| Figure 9. Results of nitrate reduction test  | 53   |
| <b>Figure 10</b> . The amplicon of <i>IS 6110</i> (123bp) on agrose gel after stained with ethidium bromide        | 54   |
| <b>Figure 11.</b> The amplicon of rpoB gene (193bp) on agrose gel after stained with ethidium bromide              | 55   |
| <b>Figure 12</b> . The amplicon of <i>IS 6110</i> (123bp) on agrose gel after stained with ethidium bromide        | 56   |
| <b>Figure 13.</b> The amplicon of rpoB gene (193bp) on agrose gel after stained with ethidium bromide              | 57   |

### **List of Tables**

| No | Description  | Page |
|----|--|------|
| 1  | Table 1; Different treatment status among enrolled | 50   |
|    | patients in Khartoum and Gazeera States            |      |
| 2  | Table 2. The result of selected biochemical tests  | 51   |